Malignant Melanoma Clinical Trials 2024

Malignant Melanoma Clinical Trials 2024

Malignant Melanoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in malignant melanoma clinical trials today.

Malignant Melanoma Clinical Trials

Here are the 0 most popular medical studies for malignant melanoma

Popular filter options for malignant melanoma trials

Malignant Melanoma Clinical Trials With No Placebo

View 6 malignant melanoma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to malignant melanoma

What are the top hospitals conducting malignant melanoma research?

When it comes to cutting-edge clinical trials in the field of malignant melanoma, several renowned hospitals are leading the way. In Toronto, Sunnybrook Health Sciences Centre is actively conducting one trial for this aggressive form of skin cancer. While they may not have any previous trials specifically focused on malignant melanoma, their dedication to research and patient care remains unwavering. Similarly, Massachusetts General Hospital Hematology Oncology in Boston is also currently engaged in one active clinical trial for this condition with no prior recorded studies. This prestigious institution's commitment to advancing treatment options for patients with malignant melanoma highlights their continuous efforts to find new breakthroughs.

Heading towards New York City, Columbia University Medical Center - New York Presbyterian Oncology Department joins the ranks with an ongoing clinical trial focusing on malignant melanoma. Like its counterparts, there haven't been any past recorded trials related exclusively to this specific type of cancer at this facility; however, their active participation demonstrates a promising step forward in finding innovative approaches against this disease.

Meanwhile, another esteemed institution making waves in cancer research is Memorial Sloan Kettering Cancer Center (MSKCC) located in New York City as well. MSKCC boasts an ongoing clinical trial dedicated solely to investigating treatment options for malignant melanoma patients—a testament to their commitment and expertise in fighting against such diseases.

Finally, California Cancer Associates For Research (cCARE), situated in Encinitas, adds itself into the mix by conducting an active clinical trial targeting malignant melanoma cases within its region while having zero previously held investigations regarding such area uncovered up until now.

While these hospitals might not yet have extensive historical records when it comes to specific trials related directly to malignant melanoma treatment options – each represents a beacon of hope and progress within the medical community's relentless pursuit of improved outcomes for individuals afflicted by this challenging form of skin cancer. Through these collaborative efforts across various locations nationwide lies the potential for groundbreaking discoveries that could transform the lives of countless individuals affected by malignant melanoma.

Which are the best cities for malignant melanoma clinical trials?

When it comes to clinical trials for malignant melanoma, several cities stand out as key players in advancing research and treatment options. New York, New York, with 2 active trials studying DYP688 and other interventions. Encinitas, California also has 2 ongoing studies exploring treatments like Rituxan/Abraxane and others. Toronto, Ontario contributes to the field with 1 active trial focused on Treatment Arm and related approaches. Lastly, Boston, Massachusetts and Palm Springs, California both have 1 active trial each investigating treatments such as DYP688 and general therapeutic strategies respectively. These cities offer patients diagnosed with malignant melanoma access to cutting-edge clinical trials that hold promise for improved outcomes in the fight against this aggressive form of skin cancer.

Which are the top treatments for malignant melanoma being explored in clinical trials?

In the realm of clinical trials for malignant melanoma, several cutting-edge treatments are currently under exploration. Leading the pack is ipilimumab, a promising drug that has gained significant attention with its effectiveness in treating this aggressive form of skin cancer. Additionally, pembrolizumab and nivolumab have emerged as formidable contenders, demonstrating their potential to combat malignant melanoma through ongoing research studies. These innovative therapies offer hope for patients fighting against this challenging disease, paving the way for improved outcomes and enhanced quality of life.

What are the most recent clinical trials for malignant melanoma?

Recent clinical trials present new hope for those affected by malignant melanoma, a form of skin cancer. Notable among them is the investigation of DYP688, a potential treatment that has progressed to Phase 2 after promising results in Phase 1. Additionally, another trial focuses on developing an effective treatment arm specifically designed for malignant melanoma patients. These advancements highlight the ongoing efforts to combat this disease and improve outcomes for individuals facing this challenging diagnosis.

What malignant melanoma clinical trials were recently completed?

Several recent clinical trials have concluded, focusing on advancing treatments for malignant melanoma. Notably, a trial sponsored by Washington University School of Medicine was completed in October 2021, investigating the efficacy of Uproleselan. Additionally, the National Cancer Institute (NCI) wrapped up their own trial in September 2021, exploring mRNA-1273 therapy for this aggressive form of skin cancer. Finally, AgenTus Therapeutics successfully completed a study on agenT-797 in January 2021. These significant advancements highlight ongoing efforts to combat malignant melanoma and offer hope to patients facing this challenging condition.